Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit

Ixaka to present in vivo gene delivery platform for CAR-T and
related bioproduction challenges at 6^th CAR TCR Summit

• CSO, Cecile Bauche, also chairing panel discussion on optimising animal models for cell therapy
• Five posters covering the application of Ixaka’s in vivo gene delivery platform to the development of CAR-T also presented as part of the CAR TCR Summit

London, UK, 31 August 2021: Ixaka Ltd, an integrated cell and gene therapy company, announces that Dr Cecile Bauche, Chief Scientific Officer, will present its in vivo gene delivery platform and the key bioproduction challenges associated with advancing an in vivo CAR-T therapy into the clinic at the 6^th CAR TCR Summit on Tuesday, 31 August, 2021 at 2.30pm ET / 11.30am PT.

Ixaka’s nanoparticle-based in vivo gene delivery technology is a highly promising platform for the development of in vivo CAR-T therapies. Dr Bauche will present on the different components of the platform and then the lessons learned from progressing Ixaka’s lead program for CD19 haematological malignancies (CELTIC) towards first-in-man clinical studies. The presentation will discuss how lentiviral vector design and bioproduction are key for in vivo gene delivery platforms and outline the anticipated regulatory pathway and associated quality controls. Dr Bauche will also chair a discussion on the development of relevant animal models for developing cell therapies at 4.00pm ET / 1.30pm PT.

“Our nanoparticle-based in vivo gene delivery technology is ideally positioned to deliver on the promise of in vivo CAR-T therapies to transform cancer treatment without the need for costly dedicated manufacturing sites for T-cell modification. The CAR TCR Summit is now one of the key events in the industry calendar, with leaders from the entire field represented. We are therefore delighted to share our latest insights from the development of an in vivo anti-CD19 CAR T-cell therapy based on a chemically encapsulated lentiviral vector,” commented Dr. Cecile Bauche, Vice President & Chief Scientific Officer, at Ixaka.

A further five posters will also be presented at the conference covering a range of applications of the nanoparticle-based in vivo gene delivery platform. In addition to further detail on the CELTIC program, progress with proprietary anti-CD3 aptamers, selected by Ixaka as targeting agents, will be made available.

Event: 6^th CAR TCR Summit

Date: 31 August 2021

Conference Link: https://car-tcr-summit.com/

Location: Online
 

Track: Manufacturing

Title: Outlining Bioproduction Challenges to Bring Ixaka’s Innovative In Vivo CAR-T into the Clinic

Time: 2.30pm ET / 11.30am PT
 

Track: Translation

Title: Optimizing Models for Cell Therapy (Chair: Cecile Bauche, CSO, Ixaka)

Time: 4.30pm ET / 1.30pm PT